# A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis

> **NCT01927263** · PHASE3 · COMPLETED · sponsor: **Nichi-Iko Pharmaceutical Co., Ltd.** · enrollment: 242 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** NI-071
- **BIOLOGICAL:** Infliximab

## Key facts

- **NCT ID:** NCT01927263
- **Lead sponsor:** Nichi-Iko Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2015-03
- **Final completion:** 2016-03
- **Target enrollment:** 242 (ACTUAL)
- **Last updated:** 2016-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01927263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01927263, "A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01927263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*